Federal Register / Vol. 66, No. 243 / Tuesday, December 18, 2001 / Notices 65215

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Neurotrophic Components of the ADNF

I Complex

Brenneman et al. (NICHD)

DHHS Reference No. E–209–01/0 filed

12 Sep 2001

Licensing Contact: Jonathan Dixon; 301/

496–7056 ext. 270; dixonj@od.nih.gov

Neuronal cell death has been

associated with a variety of diseases and

conditions, including Alzheimer’s,

AIDS-related dementia, Huntington’s

disease, and Parkinson’s disease to

name a few. Neuronal cell death has

also been associated with

developmental retardation and learning

impairments that have lifelong effects

on individuals diagnosed with these

conditions.

This invention discloses new Activity

Dependent Neurotrophic Factor I

(ADNF I) complex polypeptides.

Previously, Activity Dependent

Neurotrophic Factor (ADNF)

polypeptides have been shown to

prevent neuronal cell death. ADNF

polypeptides are secreted by astroglial

cells in the presence of vasoactive

intestinal peptide (VIP). These new

ADNF I complex polypeptides are

effective for reducing neuronal cell

death, for reducing oxidative stress, for

reducing condition(s) associated with

fetal alcohol syndrome in a subject, for

enhancing learning and memory, both

pre- and post-natally, and for other

conditions.

With these additional ADNF I

complex polypeptides it will be easier

to target specific receptors in different

cell types and to individually tailor drug

treatment regimes to those afflicted with

neurodegenerative disorders.

Utilization of FPRL1 as a Functional

Receptor by Serum Amyloid A (SAA)

Ji Ming Wang et al. (NCI)

DHHS Reference No. E–167–99/0 filed

22 Sep 1999 (PCT/US99/21770, WO

01/21188)

Licensing Contact: Marlene Shinn; 301/

496–7056 ext. 285;

shinnm@od.nih.gov

This technology identifies a means for

modulating the interaction of Serum

Amyloid A (SAA) with its functional

receptor FPRL1. This modulation may

have therapeutic applications in treating

diseases such as infections, organ

rejection, rheumatoid arthritis,

atherosclerosis, neoplasms, and

amyloidosis. The SAA, an acute phase

protein, is normally present in serum

but increases by 1,000 fold in systemic

inflammatory conditions and is

associated with leukocyte migration in

these disease states. This technology

identifies various means to modulate

the association of SAA and FPRL1 in a

SAA–FPRL1 complex or method of

identifying agents that associate with

the complex. It is available for

immediate licensing and research

collaborations via a Cooperative

Research and Development Agreement

(CRADA).

Dated: December 10, 2001.

Jack Spiegel,

Director, Division of Technology,

Development and Transfer, Office of

Technology Transfer, National Institutes of

Health.

[FR Doc. 01–31048 Filed 12–17–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Complementary

and Alternative Medicine; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Complementary and Alternative Medicine

Special Emphasis Panel NCCAM SEP ZAT1

K–02.

Date: January 4, 2002.

Time: 8:30 a.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: 2 Democracy Plaza, 6707 Democracy

Boulevard, Conference Room 701, Bethesda,

MD 20892.

Contact Person: William A. Kachadorian,

PhD., Scientific Review Administrator, Office

of Scientific Review, National Center for

Complementary and Alternative Medicine,

6707 Democracy Blvd, Ste 106, Bethesda, MD

20892–5475, (301) 594–2014,

kachadow@mail.nih.gov.

Dated: December 10, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–31047 Filed 12–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Dental and

Craniofacial Research; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: NIDCR Special Grants

Review Committee, Review of R03, F32, K02,

K08, K22, K23, K24 Grants.

Date: February 21–22, 2002.

Time: 8 AM to 5 PM.

Agenda: To review and evaluate grant

applications.

Place: Marriott Pooks Hill, 5151 Pooks Hill

Road, Bethesda, MD 20814.

Contact Person: Yujing Liu, PHD, MD,

Scientific Review Administrator, National

Institute of Dental and Craniofacial Res., 45

Center Drive, Natcher Building, Rm. 4AN44F,

Bethesda, MD 20892, (301) 594–2372.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.121, Oral Diseases and

Disorders Research, National Institutes of

Health, HHS)

Dated: December 7, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–31043 Filed 12–17–01; 8:45 am]

BILLING CODE 4140–01–M